Categories: Health

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

TAINAN, June 13, 2025 /PRNewswire/ — Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer’s disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects (Nrf2 activation), melioration of autophagy function (autolysosomal activation), anti-amyloid accumulation (β-amyloid clearance), and anti-inflammatory effects (through NF-κB inhibition) through autolysosome pathway in neurons and microglia to remove intraneuronal and extracellular amyloid accumulation, representing the first in human multi-target strategy for AD treatment.

The Phase I trial showed excellent safety, tolerability, and pharmacokinetics at 100–200 mg in both healthy and elderly adults. TML-6 will now advance to a Phase II 19 site trial across the United States, Sweden, and Taiwan after FDA approval. This 12-month study will enroll 210 patients with mild cognitive impairment (MCI) or mild dementia.

Primary endpoints will include neuropsychological assessments (CDR-SB, iADRS) and blood biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP), supported by brain MRI, amyloid PET scans, and ApoE genotyping. Type C FDA consultation for phase 2 trial design has completed on 13 May 2025, with trial initiation expected in April 2026, conducted by Syneos Health CRO.

With its strong preclinical and clinical profile, TML-6 holds promise as both a monotherapy and in combination with anti-amyloid biologics, providing new hope for patients with Alzheimer’s disease.

About Merry Life Biomedical Company

Merry Life Biomedical is a Taiwan-based biotechnology company focused on developing innovative therapies for neurodegenerative and age-related diseases. Leveraging advanced molecular design, pharmacological innovation, formulation optimization and global clinical development, the company is committed to addressing urgent unmet medical needs.

Media Contact
Dr. Ih-Jen Su
Merry Life Biomedical Company, Ltd.
Phone: +886-910-902-296
Email: suihjen0704@stust.edu.tw 

Logo – https://mma.prnewswire.com/media/2708243/Merry_Life_LOGO_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/merry-life-launches-global-phase-ii-trial-of-tml-6-the-first-drug-targeted-at-autolysosome-pathway-for-therapy-of-alzheimers-disease-302478755.html

PRNW Agency

Recent Posts

Star Power in Action: Sunil Narine Takes Centre Stage in Parimatch’s New Game

Bringing brand ambassadors into the user journey has become a powerful way to create a…

15 hours ago

Parimatch Created Cricket Festival Boxes for Fans to Enjoy the Indian T20 League to the Fullest

As the Indian T20 League reaches its peak, Parimatch, the #1 global gaming platform is…

15 hours ago

World’s Best Glacier Photos Launch in Global “Walk of Water” Exhibition

Beauty and Peril of Vanishing Glaciers Taking Centre Stage in Onewater's Global Photography Exhibition, Urging…

15 hours ago

Guangdong launches four major international communication platforms

GUANGZHOU, China, July 2, 2025 /PRNewswire/ -- On July 2, Guangdong officially launched four international communication…

15 hours ago

KuCoin Futures Ranks 4th Globally on CoinGlass’ Latest Derivatives Exchange List

VICTORIA, Seychelles, July 3, 2025 /PRNewswire/ -- KuCoin, a leading global cryptocurrency trading platform, is…

15 hours ago

SPJIMR’s PGDM Class of 2027 celebrates leadership, diversity, and purpose

New cohort embarks on a transformative journey in management and leadership MUMBAI, India, July 3,…

15 hours ago